Bingbing Li

TL;DR: The findings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the management of patients with relapsing-remitting multiple sclerosis and strengthen evidence for its beneficial effects on relapse rates in patients with relapse rates.

TL;DR: A novel primary composite endpoint was used based on change from baseline in Expanded Disability Status Scale (EDSS), 25' Timed-Walk Test, or Nine-Hole Peg Test to assess time to 3-month confirmed disability progression in study participants treated for at least 3 years.

TL;DR: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide, and this data indicates that this drug should be considered as a second-line treatment for relapsing multiple sclerosis.

TL;DR: To investigate the relationship between brain volume and disability worsening over ≥3 years in the natural history of primary progressive multiple sclerosis using data from the placebo group of the INFORMS trial, clinicaltrials.gov NCT00731692 is used.

TL;DR: The favourable benefit–risk profile of ofatumumab versus teriflunomide supports its consideration as a first-line therapy in RDTN patients.